http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010163457-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_995c71109762882f3cc26e74d8d61acf http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6404c847a4c18d6414543526d51e61f2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1825 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 |
| filingDate | 2010-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc81b4db96277f77aacae4d019aab990 |
| publicationDate | 2010-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2010163457-A |
| titleOfInvention | Unit dose FGF-2 effective for angiogenesis and methods of use |
| abstract | Disclosed are pharmaceutical compositions and methods for inducing angiogenesis in a human heart. A unit dose composition comprising 0.2 μg / kg to 48 μg / kg of FGF-2 of SEQ ID NO: 2 or an angiogenic active fragment or an angiogenic active mutein thereof in a pharmaceutically acceptable carrier. object. Method for treating a human patient for coronary artery disease (recombinant FGF-2 or angiogenic active fragment thereof in one or more coronary arteries or one peripheral vein in a stable and angiogenic effective dose Or a step of administering an angiogenic activity mutein). The single unit dose composition provides an angiogenic effect in human CAD patients that lasts 6 months before re-treatment is required. A method of administration that optimizes patient safety (fluid, heparin and / or infusion rate all play a role). [Selection figure] None |
| priorityDate | 1998-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 150.